Amyotrophic Lateral Sclerosis
Conditions
Keywords
Hypermetabolism, Mitochondrial abnormalities, Oxidant/antioxidant status
Brief summary
In Amyotrophic Lateral Sclerosis (ALS), malnutrition is frequent (16 to 50 % of the patients) and is an independent prognostic factor. One of the implicated factors is the increase of resting energy expenditure (REE) which can be found in about 50 % of ALS patients. The origin of this hypermetabolism is currently unknown but could be located in the mitochondria. In fact, some studies have found mitochondrial abnormalities and the existence of an oxidative stress. Thus, the aim of this study is to characterize the mitochondrial abnormalities and the oxidant/antioxidant status of ALS patients and to determine their relationship with the metabolic status, hypermetabolism or normometabolism. Three groups of patients will be studied : 20 hypermetabolic ALS patients, 20 normometabolic ALS patients and 20 healthy volunteers paired for age and sex.
Detailed description
In Amyotrophic Lateral Sclerosis (ALS), malnutrition is frequent (16 to 50 % of the patients) and is an independent prognostic factor. One of the implicated factors is the increase of resting energy expenditure (REE) which can be found in about 50 % of ALS patients. The origin of this hypermetabolism is currently unknown but could be located in the mitochondria. In fact, some studies have found mitochondrial abnormalities and the existence of an oxidative stress. Thus, the aim of this study is to characterize the mitochondrial abnormalities and the oxidant/antioxidant status of ALS patients and to determine their relationship with the metabolic status, hypermetabolism or normometabolism. Three groups of patients will be studied : 20 hypermetabolic ALS patients, 20 normometabolic ALS patients and 20 healthy volunteers paired for age and sex.
Interventions
PROCEDUREMitochondrial functions and oxidative stress
Sponsors
University Hospital, Limoges
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
University Hospital, Clermont-Ferrand
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* male or female * age \> 30 years * definite or probable ALS according to the El Escorial criteria, bulbar or spinal form, ALS diagnosis \< 1 year and treatment by riluzole.
Exclusion criteria
* family history of ALS, * oral, enteral or parenteral nutritional supply, * vitamin or trace element supplementation * confusing illness (cancer, diabetes, chronic infectious or inflammatory disease,thyroid disorders, recent surgery...), * current tobacco use, * alcoholism * treatment by corticosteroids, * diuretics, * anorectics * NSAIDs * cytotoxics * anticoagulants...
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| relationship between these abnormalities and the metabolic status (hypermetabolism or normometabolism). | — |
Countries
France
Contacts
Primary ContactCorinne Bouteloup, Dr
Outcome results
None listed